Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs
Open Access
- 26 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (6), ofaa196
- https://doi.org/10.1093/ofid/ofaa196
Abstract
Injecting drug use is a major driver of hepatitis C virus (HCV) spread worldwide, and the World Health Organization (WHO) has identified people who inject drugs (PWID) as a key population to target for HCV screening and care. Point-of-care (POC) hepatitis C tests and dried blood spot (DBS) sampling offer benefits for the management of patients with HCV infection by increasing HCV testing and linkage to care in different nonclinical settings. The aims of this prospective study were to evaluate the feasibility and the acceptability of use HCV ribonucleic acid (RNA) POC and fingerstick DBS testing in social-medical risk-reduction centers and to describe the cascade of care among PWID in France. Between June 2018 and February 2019, 89 consecutive HCV-seropositive PWID attending 2 drug treatment services and 1 supervised consumption room in inner Paris were invited to participate in further evaluation, undergoing a clinical review with a liver assessment and blood tests including fingerstick capillary whole blood POC HCV RNA testing and fingerstick DBS sampling. Of the 89 participants enrolled, HCV RNA was detected in 34 (38.6%) participants. Fingerstick whole blood POC RNA testing and HCV RNA detection from DBS sample were feasible and acceptable among PWID with no major difference in terms of HCV RNA detection rate. Overall, 16 participants received pan-genotypic antiviral treatment. The proportion of PWID with sustained virologic response at 12 weeks was 81.2%, with data for 3 patients still pending. One-step screening strategy based on the detection of HCV RNA would engage people in care for treatment scale-up and HCV elimination.Funding Information
- Regional Agency for Health
- Gilead Sciences
This publication has 26 references indexed in Scilit:
- Evaluation of the Abbott m2000 system for dried blood spot detection of hepatitis C virus RNAJournal of Clinical Virology, 2019
- Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in AustraliaInternational Journal of Drug Policy, 2018
- Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost‐effectiveness analysisJournal of Viral Hepatitis, 2018
- Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugsAddiction, 2018
- Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care AssayThe Journal of Infectious Diseases, 2018
- WHO guidelines on testing for hepatitis B and C – meeting targets for testingBMC Infectious Diseases, 2017
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology, 2016
- Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment MonitoringThe Journal of Infectious Diseases, 2015
- Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013The Lancet, 2014
- Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus RibavirinGastroenterology, 2006